Journal of Clinical Oncology
Articles in this Issue
A multifactorial analysis of first-author retention in ASCO accepted works.
9045 Background: Ensuring clinician oncologists remain engaged with research is an important step in maintaining optimal patient care in a rapidly changin...
Impact of time to treatment on overall survival for patients with oropharyngeal squamous cell carcinoma: A SEER database analysis.
e13879 Background: Incidence and mortality of oropharyngeal squamous cell carcinoma (OSCC) have continued to rise since the mid 2000s. Few studies have ex...
PROPAN: Bayesian dose-finding of propranolol combined with metronomic fixed-dose cyclophosphamide based on bivariate efficacy-tolerability outcomes in patients with locally advanced or metastatic angiosarcoma (LAMA): A phase I-II sequential trial by the French Sarcoma Group.
e23542 Background: Angiosarcoma is a rare, aggressive vascular malignancy with limited treatment options. Preclinical data...
Changing oncology training in Latin America: A mentorship program design and implementation.
e21031 Background: Mentorship is a valuable aspect of professional development in oncology. It has been associated with an increase in job satisfaction, s...
Diagnostic value of PET-CT for early detection of MRONJ in breast cancer patients.
e13112 Background: Antiresorptive therapy with denosumab is standard care for patients with osseous metastasized breast cancer. One of the most important...
Racial, ethnic, sex, and subspecialty demographic composition of initial fellow of the Fellow of the American Society of Clinical Oncology (FASCO) recipients through 2024.
9043 Background: Disparities in cancer care, including underrepresentation in the healthcare workforce, leadership, and recognition, remain a significant...
Financial toxicity in cancer patients in Senegal: A cross-sectional study in two care facilities.
e23031 Background: Cancer is a major public health issue due to its rising incidence and high mortality rates, despite significant therapeutic advancement...
A gene-panel blood test for the detection of colorectal adenomas and cancer.
e15728 Background: Colorectal cancer (CRC) is among the most treatable cancers, yet it remains the second leading cause of cancer deaths in men and third...
A comparative analysis of outcomes following autologous hematopoietic cell transplantation in multiple myeloma patients with CRAB versus SLiM features.
e19518 Background: Multiple Myeloma (MM) is a plasma cell disorder which evolves from neoplastic proliferation of clonal plasma cells. In 2014, Internatio...
Octreotide scintigraphy versus DOTATOC PET: Concordance of Krenning scores and implications on PRRT treatment eligibility.
e16339 Background: Peptide receptor radionuclide therapy (PRRT) is an established treatment for patients with somatostatin receptor (SSTR)-positive gastro...
Sexual function outcomes in female patients with pelvic cancers treated with definitive chemoradiotherapy versus other combined modality therapies.
e23202 Background: Sexual health is an important aspect of survivorship for female patients with pelvic cancers, yet the specific impacts of radiation the...
Effects of immediate elevation of inflammatory cytokines after platinum, pemetrexed, and pembrolizumab on antitumor efficacy in advanced non-squamous, non-small cell lung cancer.
8525 Background: Inflammatory cytokines play a crucial role in the tumor microenvironment and may serve as potential biomarkers for the sustained efficacy...
Efficacy and safety of dalpiciclib plus fulvestrant and pyrotinib in HR+, HER2-low advanced breast cancer following CDK4/6 inhibitor and aromatase inhibitor: A Bayesian optimal phase Ⅱ trial.
e13060 Background: Cross-line treatment with CDK4/6 inhibitors (CDK4/6i) is a challenging topic in breast cancer (BC). The postMONARCH study and the MAINT...
Examining the impact of socioeconomic factors on survival and treatment outcomes in primary intraocular lymphoma: Insights from the SEER database (2000–2021).
e19080 Background: Primary Intraocular lymphoma (PIOL) is a subset of primary central nervous system lymphoma, with increasing incidence and a poor progno...
Pembrolizumab in pediatric participants with relapsed or refractory microsatellite instability-high solid tumors: Results from the phase 1/2 KEYNOTE-051 trial.
10040 Background: KEYNOTE-051 (NCT02332668) is an open-label, multicohort, phase 1/2 study evaluating pembrolizumab in children with advanced cancers. Res...
AI-assisted exploration of novel non-invasive biomarkers of ICI therapy response.
e14591 Background: Immune checkpoint inhibitors (ICIs) have transformed cancer treatment, yet their efficacy varies significantly between patients, unders...
Darolutamide plus androgen deprivation therapy (ADT) in patients with high-risk biochemical recurrence (BCR) of prostate cancer: A phase 3, randomized, double-blind, placebo-controlled study (ARASTEP).
TPS5131 Background: Patients with prostate cancer treated with radiotherapy (RT) or radical prostatectomy (RP) as primary therapy may develop BCR – a pros...
Predicting teratoma histology in postchemotherapy residual lesions of non-seminoma testicular cancer (NSTC) patients using integrated CT radiomics and circulating MicroRNAs modelling.
5035 Background: Chemotherapy is the primary treatment for metastatic NSTC, but patients often have residual masses afterward. Accurate non-invasive model...
Comparison between extended and standard infusion in patients with chemotherapy-induced febrile neutropenia: A systematic review, meta-analysis and survival analysis.
e24094 Background: Febrile neutropenia is a serious and potentially life-threatening complication that often arises during chemotherapy treatment for canc...
Survival outcomes in pancreatic cancer: A single-center retrospective study in a large healthcare system.
e16395 Background: Pancreatic cancer remains a highly lethal malignancy with limited improvements in survival. This study aimed to develop a pancreatic ca...
IMMUNORARE <sup>5</sup> : A national platform of 5 academic phase II trials coordinated by Lyon University Hospital to assess the safety and the efficacy of the immunotherapy with domvanalimab + zimberelimab combination in patients with advanced rare cancers—The Peritoneal Mesotheliomas Cohort.
TPS4236 Background: In patients with rare cancers, there is an unmet medical need for investigating innovative therapeutics beyond standard first-line tre...
Efficacy and safety of XNW27011, a Claudin 18.2 targeting antibody drug conjugate with topoisomerase 1 inhibitor payload, in patients with Claudin 18.2 positive gastric/gastroesophageal junction cancer: Results from ongoing phase I/II study.
3034 Background: CLDN18.2 is a clinically validated target for cancer treatment. XNW27011 is a CLDN18.2 targeted ADC conju...
Azeliragon, a RAGE inhibitor, in combination with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma: Preliminary results of phase Ib/II CAN-201 NDG trial.
2069 Background: Azeliragon is an orally available inhibitor of the receptor for advanced glycation end-products (RAGE). RAGE pathway promotes cell prolif...
FIERCE-HN: A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of ficlatuzumab (HGF/cMET MAb) in combination with cetuximab in participants with recurrent or metastatic (R/M) HPV negative head and neck squamous cell carcinoma (HNSCC).
TPS6115 Background: Patients with HPV-negative R/M HNSCC have a worse median overall survival (OS) than HPV-positive patients and current treatments optio...
Real-world outcomes of maintenance olaparib in homologous recombination deficient, BRCA-negative, high-grade ovarian cancer: Insights from clinical practice in Russia.
e17576 Background: Currently there are no clinical data of efficacy of maintenance olaparib in patients with homologous recombination deficiency (HRD)-pos...